Scholarlink

<p>The recent emergence and global spread of the human Monkeypox virus (MPXV), including its transmission to non-endemic regions, have raised significant global health concerns. In this proof-of-concept study, we developed a recombinant protein-based MPXV vaccine candidate, employing an innovative and versatile multivalent, self-assembled nanocage protein scaffold. Two immunogenic antigens derived from the contemporary circulating MPXV strain have been incorporated into a self-assembled non-structural protein-10 (NSP-10) scaffold, expressed, and purified using an <i>Escherichia coli</i> expression system without a purification tag. The vaccine candidate elicited strong antibody responses in mice and conferred protection against the lethal Vaccinia virus in an intranasal and skin pock in vivo study. Additionally, an intranasal challenge with the MPXV strain clade IIb in immunized mice demonstrated promising outcomes, including a significant reduction in viral titres and eliciting a robust neutralizing antibody response. This study demonstrates a feasible, scalable, and cost-effective approach for the development of the MPXV vaccine.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月6日

查看全文
  • Rahul Ahuja,
  • Preeti Vishwakarma,
  • Varun Kumar,
  • Ritika Khatri,
  • Ananya Chatterjee,
  • Surbhi Mishra,
  • Zaigham Abbas Rizvi,
  • Anup Singh,
  • Gurleen Kaur,
  • Vikas Maithil,
  • Kunal Tarane,
  • Akanksha Chauhan,
  • Sarjeet Singh,
  • Pooja Yadav,
  • Devendra Yadav,
  • Sangita Kumari Sinha,
  • Syed Khalid Ali,
  • Abhisek Chatterjee,
  • Priyanka Priyadarsiny,
  • Amit Awasthi,
  • Vidya Mangala Prasad,
  • Shubbir Ahmed,
  • Sweety Samal

摘要

The recent emergence and global spread of the human Monkeypox virus (MPXV), including its transmission to non-endemic regions, have raised significant global health concerns. In this proof-of-concept study, we developed a recombinant protein-based MPXV vaccine candidate, employing an innovative and versatile multivalent, self-assembled nanocage protein scaffold. Two immunogenic antigens derived from the contemporary circulating MPXV strain have been incorporated into a self-assembled non-structural protein-10 (NSP-10) scaffold, expressed, and purified using an Escherichia coli expression system without a purification tag. The vaccine candidate elicited strong antibody responses in mice and conferred protection against the lethal Vaccinia virus in an intranasal and skin pock in vivo study. Additionally, an intranasal challenge with the MPXV strain clade IIb in immunized mice demonstrated promising outcomes, including a significant reduction in viral titres and eliciting a robust neutralizing antibody response. This study demonstrates a feasible, scalable, and cost-effective approach for the development of the MPXV vaccine.